NEW YORK, July 10, 2017 /PRNewswire/ —
Q BioMed Inc. (QBIO) will be featured on CEO Clips airing on Bloomberg Television July 10 through 14th. CEO Clips, profiles some of the most innovative publicly traded companies in North America and will feature a :15 to :30 sec clip about Q BioMed on Bloomberg Television beginning today and run through July 14th.
This clip can seen here: http://www.b-tv.com/q-biomed-commercial-30sec/
Please sign up for company updates at https://qbiomed.com to stay informed and up-to-date with company developments.
Follow us on Twitter @QBioMed
About Bloomberg Television:
Bloomberg Television is a 24-hour news cable television channel in the United States and Canada which reaches 67 million viewers and is #1 for Top Management, Investors and Financial Advisors.
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to be providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are:u risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.
SOURCE Q BioMed Inc.